Novo Nordisk’s Pipeline Paradox: A $55 Billion Bet on Automation and a Quiet Drug Revolution

Despite pricing pressure and Lilly competition, Novo Nordisk's aggressive capex, Medicare expansion, and promising pipeline (oral Wegovy, Zenagamtide, Etavopivat) suggest a potential turnaround.

The market has handed Novo Nordisk a brutal 40% haircut over the past year, and the bears have plenty of ammunition. Pricing pressure from US payers, a resurgent Eli Lilly snapping up more than 60% of the GLP-1 market, and a CagriSema weight-loss result that trailed Zepbound by 2.5 percentage points have all fuelled the narrative of a company in retreat. But the stock’s recent bounce — a 3.21% gain to €38.90 on Friday — hints at a more complicated story unfolding beneath the surface.

The same week that saw the shares claw back above their 50-day moving average of €36.99 also revealed a company spending aggressively to reshape its future. Novo Nordisk has earmarked a jaw-dropping 55 billion Danish kroner in capital expenditure for 2026, a sum that underlines a radical operational overhaul. New factories are coming online — a 3.5-billion-kroner facility in Bohumil, Czech Republic, and a $29 million investment in Tianjin, China — even as the company cuts 9,000 jobs. The logic is blunt: fully automated mass production is the only way to compete with Eli Lilly on cost and scale.

That capital splurge comes as the US government prepares to throw open a new market. From July 1, 2026, Medicare will cover obesity drugs for certain patients, a structural expansion that could dramatically swell prescription volumes. Yet the same policy carries a double edge: the Centers for Medicare & Medicaid Services is cementing its drug price negotiation programme, and expensive biologics could face mandatory price cuts from 2029. Novo Nordisk has already slashed prices for government-sponsored insurance and cash-payers, creating a calculated gamble that lower co-pays will drive disproportionate prescription growth.

The bear case is loud, but it ignores a pipeline that has quietly deepened. The oral Wegovy pill has racked up more than three million prescriptions in just five months in the US — one of the strongest pharmaceutical launches by volume in recent memory. International rollouts are slated for the second half of 2026. Meanwhile, at the ADA Congress in New Orleans, Novo Nordisk presented Phase 2 data for Zenagamtide, a next-generation candidate. The 40 mg dose cut HbA1c by 1.71 percentage points over 36 weeks, pushed nearly 89% of participants below the clinically relevant 7% threshold, and delivered a 14.6% weight loss. Phase 3 trials begin later this year.

Perhaps the most overlooked asset is Etavopivat, a potential first-in-class therapy for sickle cell disease. In April, pivotal Phase 3 data from the HIBISCUS study showed it reduced vaso-occlusive crises by 27% versus placebo, with median time to first crisis stretching to 38.4 weeks compared with 20.9 weeks for placebo. Novo Nordisk plans to file for approval in the second half of 2026. The drug came with the $1.1 billion acquisition of Forma Therapeutics in 2022, and a separate Phase 2 trial in beta-thalassemia is ongoing. For a disease affecting roughly eight million people globally, Etavopivat represents a market many analysts have yet to price in.

On the capital management front, the company has been actively buying back shares — 19.9 million B-shares for 5.27 billion kroner since February, as part of a 15-billion-kroner annual programme. Technically, the stock has stabilised: it sits above both its 50-day and 100-day moving averages, and the relative strength index of 58.2 suggests room to run without overheating. The 200-day average at €41.16 remains the crucial hurdle; a sustained close above that level would signal a genuine trend shift. From the March low of €30.25 — the 52-week trough — the shares have already recovered nearly 29%, yet they are still down roughly 13% year-to-date.

Novo Nordisk’s current valuation reflects a near-single thesis: GLP-1 growth has peaked, pricing power has evaporated, and Lilly has won. That narrative is not so much wrong as it is incomplete. A company launching a record-breaking oral pill, advancing a Phase 3-ready amylin analogue, publishing strong diabetes data in top-tier journals like The Lancet, and preparing a first-in-class regulatory submission for sickle cell disease is not a company with an exhausted pipeline. The worst of the re-rating may well be behind it, but the road back to old highs depends entirely on execution. For now, the breadth of the business is simply not showing up in the share price.